Chiara Nardon

Prof. Dr. Chiara Nardon

Department of Biotechnology, University of Verona, Strada Le Grazie, 15, 37134 Verona - Italy

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2013 in Journal of Inorganic Biochemistry
Verified
Journal Article
Closed access
Jian ZuoJian Zuo
Jian Zuo
CBCaifeng Bi
Caifeng Bi
YFYuhua Fan
Yuhua Fan
DBDaniela Buac
Daniela Buac
CNChiara Nardon
Chiara Nardon
Q. Ping DouQ. Ping Dou
Q. Ping Dou

1 September 2012 in Mini-Reviews in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
ENEszter Márta Nagy
Eszter Márta Nagy
LRLuca Ronconi
Luca Ronconi
CNChiara Nardon
Chiara Nardon
DFDolores Fregona
Dolores Fregona
To date, cisplatin and its analogs are among the most effective chemotherapeutic agents for cancer treatment. However, high systemic toxicity and the propensity for patients to develop tumor resistance remain the main challenges in the clinical application. Therefore, the discovery and development of novel active chemotherapeutic agents are largely needed and the research of new metal-based anticancer drugs continues to be a very active international field. In this review paper we aim to give a detailed overview on our research work devoted to the design of novel dithiocarbamato complexes with different noble metals (such as palladium, platinum, copper, ruthenium and gold), which have gained considerable interest in both the development and the treatment of cancer. In particular, we summarize the results of the metal complexes achieved so far, focusing on the gold(III) compounds, that show outstanding in vitro and in vivo antitumor properties and reduced, or even no, systemic and renal toxicity, compared to the reference drug cisplatin.

6 February 2012 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
MKMorelle Negom Kouodom
Morelle Negom Kouodom
LRLuca Ronconi
Luca Ronconi
MCMarta Celegato
Marta Celegato
CNChiara Nardon
Chiara Nardon
LMLuciano Marchiò
Luciano Marchiò
DFDolores Fregona
Dolores Fregona

15 March 2012 in Future Medicinal Chemistry
Verified
Journal Article
Closed access
Lisa Dalla ViaLisa Dalla Via
Lisa Dalla Via
CNChiara Nardon
Chiara Nardon
DFDolores Fregona
Dolores Fregona
Proteasomes are large multicatalytic complexes endowed with proteinase activity, located both in the cytosol and in the nucleus of eukaryotic cells. The ubiquitin-proteasome system is responsible for selective degradation of most intracellular proteins and therefore plays an essential regulatory role in many critical cellular processes. The proteasomal activity can also contribute to the pathological states of many diseases, including inflammation, neurodegeneration and cancer, through a disregulation in the level of regulatory proteins. These diseases may be targeted by modulating components of the ubiquitin-proteasome pathway, using small molecules as inhibitors. Bortezomib (Velcade(®)), used for the treatment of relapsed multiple myeloma, is the first and, up to now, the only proteasome inhibitor approved by the US FDA. Nowadays, the discovery that some metal-based complexes exert their antiproliferative action by affecting proteasomal activities provides the possibility of developing new opportunities in cancer therapy.

2 January 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
CNChiara Nardon
Chiara Nardon
SSSara M. Schmitt
Sara M. Schmitt
HYHuanjie Yang
Huanjie Yang
Jian ZuoJian Zuo
Jian Zuo
DFDolores Fregona
Dolores Fregona
Q. Ping DouQ. Ping Dou
Q. Ping Dou
Since the serendipitous discovery of cisplatin, platinum-based drugs have become well-established antitumor agents, despite the fact that their clinical use is limited by many severe side-effects. In order to both improve the chemotherapeutic index and broaden the therapeutic spectrum of current drugs, our most recent anti-neoplastic agents, Au(III) complexes, were designed as carrier-mediated delivery systems exploiting peptide transporters, which are up-regulated in some cancers. Among all, we focused on two compounds and tested them on human MDA-MB-231 (resistant to cisplatin) breast cancer cell cultures and xenografts, discovering the proteasome as a major target both in vitro and in vivo. 53% inhibition of breast tumor growth in mice was observed after 27 days of treatment at 1.0 mg kg−1 d−1, compared to control. Remarkably, if only the most responsive mice are taken into account, 85% growth inhibition, with some animals showing tumor shrinkage, was observed after 13 days. These results led us to file an international patent, recognizing this class of gold(III) peptidomimetics as suitable candidates for entering phase I clinical trials.

1 January 2014
Verified
Journal Article
Closed access
CNChiara Nardon
Chiara Nardon
GBGiulia Boscutti
Giulia Boscutti
DFDolores Fregona
Dolores Fregona